No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users.

A cross-sectional analysis from Yale School of Medicine estimates that approximately 5.8 million adolescents and 11.1 million ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.

Divi's Laboratories, India’s second-largest pharma company by market cap, is expected to report impressive revenue and profit ...

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...